COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targetedCOPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted

Curasight to present at TD Cowen’s 46th Annual Health Care Conference in Boston

2026/02/17 15:15
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston. 

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is a major investor conference where public and private healthcare companies meet with institutional investors, and large pharma via scheduled 1×1 meetings and presentations combined with fireside chats and innovative panel discussions.

About Curasight A/S

Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454

The following files are available for download:

https://mb.cision.com/Main/19744/4308454/3937544.pdf

260217 Curasight Press release – TDCowen

Cision View original content:https://www.prnewswire.com/news-releases/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston-302689307.html

SOURCE Curasight

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004076
$0.0004076$0.0004076
-3.45%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Unlimit Appoints Irene Skrynova as CEO, Global Payments

Unlimit Appoints Irene Skrynova as CEO, Global Payments

Unlimit announced the appointment of Irene Skrynova as CEO, Global Payments, as the company accelerates its evolution into a global financial infrastructure platform
Share
ffnews2026/03/12 18:17
Economic policies are chasing investors away from US – Mercer

Economic policies are chasing investors away from US – Mercer

The post Economic policies are chasing investors away from US – Mercer appeared on BitcoinEthereumNews.com. A wave of clients are shifting away from U.S. assets as investors react to President Donald Trump’s trade and interest-rate agenda, according to Mercer LLC. The consulting firm says concern over tariffs, pressure on the Federal Reserve, a swelling budget deficit and the risk of a softer dollar are pushing money to Europe, Japan and other markets. Hooman Kaveh, Mercer’s global chief investment officer, said a rising share of the firm’s 3,900 clients, together overseeing about $17 trillion, are reducing U.S. exposure. The opening weeks in the early phase of Trump’s second term “has been a trigger for genuine diversification,” he noted in an interview this week. “We’re certainly seeing that in client portfolios where flows are toward diversifying markets, geographies, asset classes, currencies.” Market nerves were evident in early April after Trump’s “Liberation Day” announcement, when both U.S. stocks and Treasuries fell before rebounding. Even so, U.S. shares have trailed many overseas benchmarks in 2025 for dollar-based investors. Kaveh said investors are struggling to price the tariff path because the effects can cut two ways: either squeeze company margins or get passed through to consumers and lift inflation. “If you have a situation where tariffs are going to push prices up, and the weaker dollar potentially can increase inflation, that would cause the Fed much more of a challenge to cut rates,” he added. As mentione in a Bloomberg report, he called the White House’s preference for a weaker dollar “the Achilles heel to the current approach” since it can magnify the inflation impulse from tariffs. Where the money is going Trump’s repeated criticism of Chair Jerome Powell, saying he has been slow to lower borrowing costs, along with the president’s move to fire Governor Lisa Cook, is further encouraging clients to step back from the U.S., according to…
Share
BitcoinEthereumNews2025/09/18 13:17
UiPath (PATH) Stock Slides 5% Despite Crushing Earnings on Every Metric

UiPath (PATH) Stock Slides 5% Despite Crushing Earnings on Every Metric

TLDR UiPath beat Q4 estimates with EPS of $0.30 vs $0.26 expected, and revenue of $481M vs $465M expected The stock fell more than 5% in premarket trading despite
Share
Coincentral2026/03/12 18:09